NCT06032078 is a NA clinical trial of Cutera laser machine in Keratosis Pilaris, sponsored by Premier Specialists, Australia.

Who is sponsoring NCT06032078?

NCT06032078 is sponsored by Premier Specialists, Australia.

What drugs are being tested in NCT06032078?

Interventions in NCT06032078: Cutera laser machine.

What condition does NCT06032078 study?

NCT06032078 studies Keratosis Pilaris.

Is NCT06032078 still recruiting?

NCT06032078 is currently status unknown. Last updated 11 September 2023.

Last reviewed 2023-09-11 · How we verify

NCT06032078

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris

Status unknown NA Last updated 11 September 2023

What this trial tests

NA trial testing Cutera laser machine in Keratosis Pilaris in 15 participants. Status unknown.

Timeline

26 July 2023

Primary endpoint
29 December 2023

29 December 2023

Quick facts

Lead sponsor	Premier Specialists, Australia
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	other
Enrollment	15
Start date	26 July 2023
Primary completion	29 December 2023
Estimated completion	29 December 2023
Sites	2 locations across Australia

Drugs / interventions tested

Cutera laser machine

Conditions studied

Keratosis Pilaris — all drugs for Keratosis Pilaris →

Sponsor

Premier Specialists, Australia — full company profile →

Who can join

18 and older, any sex, with Keratosis Pilaris. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective study aims to evaluate the responsiveness of the validated investigator global assessment (IGA) and composite area index score for keratosis pilaris by data collection through treatment and scoring sessions held at a private practice and relevant statistical analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Premier Specialists, Australia trials

Trials by the same sponsor.

NCT05534776 — Validation of 5-Point Investigator Global Assessments for Pemphigus · unknown
NCT05535517 — Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris · unknown
NCT04971200 — Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo · EARLY_PHASE1 · completed
NCT05525065 — Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs) · unknown
NCT07228481 — Study of Two Dosages of Roaccutane in Cystic Acne · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06032078 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Premier Specialists, Australia
Last refreshed: 11 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06032078.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing